KMTS — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-09-14

• We are a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. We have developed and are commercializing the Cardiac Recover…

• In December 2025, we completed a public underwritten offering and issued an aggregate of 6,900,000 Common Shares at a price of $23.00 per share, resulting in net proceeds of $149.3 million, after deducting underwriting discounts but before expenses.

• We have invested heavily in developing and commercializing our Cardiac Recovery System platform. We have also made significant investments in clinical studies to demonstrate the safety and effectiveness of our ASSURE® WCD and to support applications for regulatory approvals. We have made and will co…

• Loss on debt extinguishment consists relates to the refinancing transaction completed in connection with the 2026 Term Loan and the repayment of the Term Loan 2024. The amount recognized represents the difference between the reacquisition price of the extinguished debt and its net carrying amount.

• Revenue for the three months ended July 31, 2026 increased by $11.6 million, or 60%, compared to the three months ended July 31, 2025. Revenue growth was primarily driven by an increase in the number of patients using our products.

Text removed vs the prior filing · source: 10-Q · 2026-03-17

• We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing ou…

• We have invested heavily in developing and commercializing our Cardiac Recovery System platform. We have also made significant investments in clinical studies to demonstrate the safety and effectiveness of our ASSURE WCD and to support applications for regulatory approvals. We have made and will con…

• Net loss and comprehensive loss attributable to Kestra Medical Technologies, Ltd.

• Net loss and comprehensive loss attributable to Kestra Medical Technologies, Ltd.

• Net loss attributable to common shareholders, basic and diluted

Text added vs the prior filing · source: 10-Q · 2026-09-14

• Remediation Efforts to Address Previously Identified Material Weaknesses

• Management, with oversight from the Audit Committee, and assistance from third party experts, continues to implement measures designed to remediate the material weaknesses described above. We have taken and will continue to take action to remediate these material weaknesses, including:

• Enhancing the Company's accounting, finance and IT functions through the hiring of personnel with appropriate and sufficient technical expertise. Since the material weakness was identified, the Company has increased the size and experience of these functions based on the Company's financial reportin…

• Designing and implementing controls related to non-routine or complex transactions, to ensure these are properly presented and classified, including items referred to above;

• Designing and implementing controls to address segregation of duties risks over manual journal entries and account reconciliations, including controls designed to ensure that manual journal entries and account reconciliations are subject to independent review by individuals without conflicting acces…

Text removed vs the prior filing · source: 10-Q · 2026-03-17

• We continue to make progress towards remediating these material weaknesses. These remediation measures are ongoing as of the date of this Form 10-Q and include: hiring additional personnel, such as financial planning and accounting, compliance, information technology, and other professionals with ap…

• We continue to evaluate current and projected resource needs on a regular basis, hire additional qualified resources as needed and have engaged third parties and other professionals to assist with the resolution of IT general controls and governance processes. Our ability to maintain qualified and a…

• The material weaknesses will not be considered remediated until management completes the design and implementation of the measures described above and the controls operate for a sufficient period of time and management has concluded, through testing, that these controls are effective.

• There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act during the quarter ended January 31, 2026 that have materially affected, or are reasonably likely to materially affect, ou…